

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A drug/gene eluting stent comprising a layer containing a gene encoding a hybrid polypeptide on the surface.
2. (Original) The drug/gene eluting stent according to claim 1, wherein the hybrid polypeptide is a binding of a fibronectin-derived collagen binding domain (FNCBD) polypeptide and an anti-inflammatory factor or an angiogenic factor.
3. (Currently Amended) The drug/gene eluting stent according to claim 1-~~or~~ 2, wherein the hybrid polypeptide is a bound product of an anti-inflammatory factor or an angiogenic factor to a carboxyl terminal of FNCBD.
4. (Currently Amended) The drug/gene eluting stent according to claim 2-~~or~~ 3, wherein the anti-inflammatory factor is a N-terminal deleted chemokine.
5. (Original) The drug/gene eluting stent according to claim 4, wherein the N-terminal deleted chemokine is N-terminal deleted compound (7ND) of a monocyte chemoattractant protein-1 (MCP-1).

July 14, 2006

6. (Currently Amended) The drug/gene eluting stent according to ~~any one of~~  
~~claims~~claim 1 to 5, wherein the gene encoding the hybrid polypeptide has the sequence  
shown in SEQ ID No: 1 or 2.

7. (Currently Amended) The drug/gene eluting stent according to ~~any one of~~  
~~claims~~claim 1 to 6, characterized by being used for treatment of vascular restenosis,  
acute coronary syndromes or cerebral ischemia.

8. (Original) The drug/gene eluting stent according to claim 7, wherein the  
vascular restenosis is a relapsed stenosis of post percutaneous transluminal coronary  
angioplasty (PTCA) or percutaneous transluminal angioplasty (PTA).

9. (Currently Amended) A method for treating vascular restenosis, acute  
coronary syndromes or cerebral ischemia, which comprises using the drug/gene eluting  
stent according to ~~any one of~~ claims claim 1 to 6.

10. (Currently Amended) Use of the drug/gene eluting stent according to ~~any~~  
~~one of~~ claims claim 1 to 6 for manufacturing an agent for treating vascular restenosis,  
acute coronary syndromes or cerebral ischemia.